Omeros (OMER) Common Equity (2010 - 2026)
Omeros (OMER) posted Common Equity of -$63.3 million for Q1 2026, up 47.76% sequentially from -$121.2 million in Q4 2025, and up 70.34% YoY from -$37.2 million in Q1 2025.
Omeros (OMER) Common Equity (2010 - 2026) Analysis & Trends
Omeros has reported Common Equity for 17 years, with the latest figure at -$63.3 million in Q1 2026.
- Quarterly Common Equity rose 70.34% year-over-year to -$63.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$63.3 million (up 70.34% YoY) and the FY2025 annual result came in at -$121.2 million, up 33.61% from the prior year.
- Common Equity improved to -$63.3 million in Q1 2026 per OMER's latest filing, from -$121.2 million in the prior quarter.
- Over five years, Common Equity peaked at $85.7 million in Q4 2022 and troughed at -$228.7 million in Q2 2025.
- A 5-year average of -$78.9 million and a median of -$63.3 million in 2026 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity soared 1215.45% in 2023, then sank 1005.02% in 2024.
- Over 5 years, Common Equity stood at $85.7 million in 2022, then plunged by 129.16% to -$25.0 million in 2023, then sank by 630.93% to -$182.6 million in 2024, then soared by 33.61% to -$121.2 million in 2025, then soared by 47.76% to -$63.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$63.3 million, -$121.2 million, and -$220.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | -51.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.35 Mn |
| Mar 31, 2026 | -63.33 Mn |
| Dec 31, 2025 | -121.23 Mn |
| Sep 30, 2025 | -220.48 Mn |
| Jun 30, 2025 | -228.69 Mn |
| Mar 31, 2025 | -213.55 Mn |
| Dec 31, 2024 | -182.61 Mn |
| Sep 30, 2024 | -154.17 Mn |
| Jun 30, 2024 | -124.60 Mn |
| Mar 31, 2024 | -71.33 Mn |
| Dec 31, 2023 | -24.98 Mn |
| Sep 30, 2023 | -13.95 Mn |
| Jun 30, 2023 | 20.51 Mn |
| Mar 31, 2023 | 54.94 Mn |
| Dec 31, 2022 | 85.68 Mn |
| Sep 30, 2022 | -46.31 Mn |
| Jun 30, 2022 | -32.70 Mn |
| Mar 31, 2022 | -4.93 Mn |
| Dec 31, 2021 | 23.78 Mn |
| Sep 30, 2021 | -262.70 Mn |